Kura Oncology, Inc. (NASDAQ:KURA Get Rating) Equities research analysts at Brookline Capital Management boosted their Q2 2023 earnings per share (EPS) estimates for shares of Kura Oncology in a research note issued to investors on Wednesday, June 14th. Brookline Capital Management analyst L. Cann ...

35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations achieved a CR on ziftomenib Ziftomenib monotherapy drives durable remissions, with median DoR of 8.2 ...

Shares of Kura Oncology, Inc. (NASDAQ:KURA Get Rating) have earned a consensus recommendation of Moderate Buy from the six brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy ...

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is...

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results ...